Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis
Go back to Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis| AbbVie (NYSE: ABBV) | Delayed: 230.01 +13.52 (6.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $216.49 | 52 Week High | $68.12 | |||
| Open | $221.94 | 52 Week Low | $50.71 | |||
| Day High | $232.32 | P/E | 49.89 | |||
| Day Low | $221.94 | EPS | $4.61 | |||
| Volume | 9,702,418 | |||||
| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 199.71 +3.13 (1.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $196.58 | 52 Week High | $333.65 | |||
| Open | $199.48 | 52 Week Low | $223.02 | |||
| Day High | $200.98 | P/E | 25.57 | |||
| Day Low | $194.74 | EPS | $7.81 | |||
| Volume | 1,669,600 | |||||
